MARKET

CSII

CSII

Cardiovascular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.97
+2.06
+5.58%
After Hours: 38.97 0 0.00% 16:00 04/08 EDT
OPEN
37.58
PREV CLOSE
36.91
HIGH
39.50
LOW
36.97
VOLUME
238.34K
TURNOVER
--
52 WEEK HIGH
55.22
52 WEEK LOW
26.00
MARKET CAP
1.37B
P/E (TTM)
-188.0792
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CSII stock price target is 51.20 with a high estimate of 60.00 and a low estimate of 42.00.

EPS

CSII News

More
  • Benzinga's Top Upgrades, Downgrades For April 7, 2020
  • Benzinga · 1d ago
  • Cardiovascular Systems (CSII) Presents At Barclays Global Healthcare Conference - Slideshow
  • Seeking Alpha - Article · 03/12 14:52
  • Why Is Cardiovascular Systems (CSII) Down 10.8% Since Last Earnings Report?
  • Zacks · 03/06 16:30
  • Cardiovascular Systems (CSII) Presents At SVB Leerink Global Healthcare Conference - Slideshow
  • Seeking Alpha - Article · 03/03 21:43

Industry

Medical Equipment, Supplies & Distribution
+4.21%
Healthcare Equipment & Supplies
+4.01%

Hot Stocks

Symbol
Price
%Change

About CSII

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
More

Webull offers kinds of Cardiovascular Systems Inc stock information, including NASDAQ:CSII real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSII stock news, and many more online research tools to help you make informed decisions.